Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$1.00 USD
+0.02 (2.19%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.00 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LUCD 1.00 +0.02(2.19%)
Will LUCD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LUCD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LUCD
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
LUCD: What are Zacks experts saying now?
Zacks Private Portfolio Services
908 Devices Inc. (MASS) Reports Q1 Loss, Misses Revenue Estimates
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
Other News for LUCD
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 | ...
Lucid Diagnostics (LUCD) Awaits Medicare Coverage for EsoGuard Test
Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG
Lucid Diagnostics (LUCD) Set for Boost with Upcoming Medicare Approval
BTIG buyers of Lucid Diagnostics ahead of Medicare coverage